γδ T cells can flexibly switch between glycolysis and oxidative phosphorylation (OXPHOS): glycolysis supports IFN-γ-producing γδ T cells (γδIFN) for anti-tumor activity, whereas OXPHOS favors IL-17-producing γδ T cells (γδ17), allowing adaptation to pro-tumor niches. Here, IL17A is linked to neoplasm.